Osteoprotegerin (OPG), a key regulator of bone resorption, is hypothesized to have a role in prostate cancer (CaP) bone metastasis. As advanced CaP is treated by androgen ablation, we examined if androgen modulates OPG expression by CaP cell lines in vitro. Basal levels of secreted OPG protein were significantly greater in androgen-independent PC-3 cells compared with androgen-responsive LNCaP-FGC cells (Po0.001); OPG was not detected in the androgenresponsive CaP cell lines LAPC-4 or DuCaP. Treatment with 5a-dihydrotestosterone (5a-DHT) significantly decreased OPG protein levels in both PC-3 and LNCaP-FGC, with maximal suppression using 10 À9 -10 À7 M 5a-DHT in PC-3 (Po0.01; day 3), and using 10 À10 -10 À9 M 5a-DHT in LNCaP-FGC cells (Po0.01; day 6). OPG messenger RNA levels were not significantly altered by this 5a-DHT treatment. Co-treatment with 10 À6 M flutamide blocked 5a-DHT inhibition of OPG protein expression in LNCaP-FGC cells. These data suggest that androgen may modulate OPG protein levels in CaP cells lines in vitro using a post-transcriptional mechanism.
Introduction
Metastasis to the bone is a significant problem in prostate cancer (CaP), which reduces patient survival and quality of life, and often causes spinal compression, pain and pathological fractures. 1 The presence of bone metastases is strongly associated with the high mortality rate in advanced CaP, with up to 84% of patients who die of the disease exhibiting skeletal metastasis. 2 Although the mechanisms by which CaP induces bone lesions are not known, the interaction between CaP and normal bone cells is thought to be an important prerequisite for bone metastasis. 3, 4 In particular, bone resorption may play a significant role in CaP bone metastasis: CaP metastatic lesions form at sites of previous osteolytic activity, 5, 6 which may be a requirement for subsequent osteoblastic activity. 6 CaP is initially dependent on androgens for growth, so a major treatment undertaken for disseminating or recurrent CaP is androgen ablation therapy by pharmaceutical castration or by bilateral orchiectomy. 2, 7 Androgen ablation causes remission in androgen-dependent tumors and is the mainstay of treatment for progressive CaP. 2, 7, 8 In many patients with bone metastasis, the cancer has already progressed to an androgen-independent phenotype and no longer responds to treatment. 2 Furthermore, male hypogonadism and osteopenia are common complications of prolonged androgen ablation and can result in weakening of the skeleton. 2, 9, 10 In healthy adult human bone, the process of bone removal is tightly regulated at the molecular level. Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily that acts as a soluble decoy receptor for receptor activator of nuclear factor-kB ligand (RANKL), [11] [12] [13] thereby inhibiting the obligate interaction between RANKL and its cognate receptor RANK that is necessary for osteoclastogenesis, osteoclast maturation, activation and survival and bone resorption. 12, 13 Immunohistochemical studies suggest that both RANKL and OPG are present in CaP in patients, with significantly elevated levels of OPG detected in bone metastases when compared with primary tumors and metastases from non-osseous sites.
14 Furthermore, serum OPG levels in patients with advanced CaP are increased when compared with patients with localized CaP, [15] [16] [17] [18] whereas serum RANKL levels do not differ significantly between these two groups. 17 These data suggest that increased OPG expression is associated with progression to bone metastases in CaP.
CaP cell lines in vitro also express OPG. The androgenindependent cell lines PC-3 and DU 145 produce markedly greater OPG than the androgen-responsive cell line LNCaP-FGC, 4, 19 suggesting that the lack of androgen response may correlate with OPG production. Treatment of osteoblastic cells with androgen has been shown to cause a small but significant decrease in OPG expression, suggesting that hormones may directly regulate OPG levels in these cells. 20 If production of OPG by CaP cells is similarly hormone-regulated, this implies that androgen ablation, the mainstay treatment for advanced CaP, may result in deregulated bone resorption local to bone metastases. Therefore, in this study, we investigated whether androgen regulates OPG production in CaP cell lines in vitro.
Materials and methods

Reagents
Unless otherwise indicated, all biochemical reagents were from Sigma-Aldrich (Sydney, NSW, Australia) and all tissue culture media and supplements were from Invitrogen Australia (Mulgrave, VIC, Australia).
Cell lines
The human CaP cell lines, PC-3 and LNCaP-FGC (both cultured in Roswell Park Memorial Institute (RPMI) supplemented with 10% fetal bovine serum (FBS)), and the immortalized human prostate line, PZ-HPV-7 (cultured in keratinocyte-serum-free medium), were purchased from the American Type Culture Collection (ATCC; Rockville, MD, USA). The LNCaP cell line, which was used in this study as a positive control for androgen receptor (AR) expression, was provided by Professor Leland Chung (Emory University, USA) and was cultured in T-medium. The DuCaP (grown in Dulbecco's modified Eagle's medium) and LAPC-4 (grown in Iscove's-modified Dulbecco's medium) CaP cell lines were obtained from Dr Kenneth Pienta (University of Michigan, USA) and Professor Charles Sawyer (University of California, USA), respectively. As phenol red possesses mild estrogenic properties, 21 phenol red-free media were used for all 5a-dihydrotestosterone (5a-DHT) treatment experiments.
OPG ELISA
All five cell lines were seeded at 10 5 cells/well in six-well plates and left overnight to adhere before washing cells once with phosphate-buffered saline (PBS) and culturing them for 4 days in phenol red-free media to determine basal OPG protein levels. Following plating and overnight adherence, LNCaP-FGC or PC-3 cells were cultured in phenol red-free RPMI with 0.1% FBS (prfRPMI) containing 10 À11 -10 À7 M 5a-DHT or 0.1% ethanol for 3 or 6 days. Conditioned medium was cleared by centrifugation before being tested for OPG levels by enzyme-linked immunosorbent assay (ELISA). In 5a-DHT/flutamide co-treatment experiments, cells were pretreated for 60 min with 10 À6 M flutamide or vehicle before addition of 10 À9 M 5a-DHT plus 10 
À11
-10 À7 M 5a-DHT or 0.1% ethanol (vehicle) in prfRPMI. In 5a-DHT/flutamide co-treatment experiments, cells were pretreated for 60 min with 10 À6 M flutamide or vehicle before addition of 10 À9 M 5a-DHT. Control cells were treated with vehicle alone. All treatment media were replaced on day 3. Following 6 days of treatment, viability was indirectly determined using the WST-1 colorimetric assay, as per the manufacturer's instructions (Roche, Basel, Switzerland; distributed by Scientifix, Cheltenham, VIC, Australia).
RT-PCR
LNCaP-FGC and PC-3 cells were seeded at 5 Â 10 5 cells per 60 mm dish, left overnight, washed once with PBS, then treated for 48 h with 10
À7 M 5a-DHT or vehicle in prfRPMI for 5a-DHT dose-response experiments or with prfRPMI containing 10 À9 M 5a-DHT or vehicle for 0, 6, 12, 24, 48 or 72 h for time course experiments. OPG and AR messenger RNA (mRNA) levels were determined by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated from the cells using TriReagent according to the manufacturer's instructions (Invitrogen Australia, Mulgrave, VIC, Australia): 5 mg were reverse-transcribed and subjected to hotstart PCR using previously published primers for OPG (548 bp amplicon), 14 AR 22 and the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPdH). 23 PCR analysis of PC-3 and LNCaP-FGC OPG mRNA was performed at 25 and 28 cycles, respectively, in the linear phase of amplification. Linear amplification of GAPdH used 21 cycles. AR mRNA expression levels were tested over 27-36 cycles of amplification. PCR products were separated by electrophoresis on 1.5% agarose gels, visualized using ethidium bromide and individual bands were quantified using Kodak 1D software V.3.6 (Eastman Kodak, New Haven CT, USA).
Western blot analysis
Whole-cell lysates were prepared from 4 Â 10 5 LNCaP-FGC and PC-3 cells using mammalian protein extraction reagent (M-PER, Pierce), used according to the manufacturer's instructions. One hundred micrograms of total protein per sample, as determined using the Bicinchonic Acid Protein Assay (Rockford, Illinois, USA; distributed by Quantum Scientific, Milton, QLD, Australia), were separated in duplicate 6% polyacrylamide gels alongside broad-range prestained molecular weight markers (New England Biolabs, Beverly, MA, USA; distributed by Genesearch, Arundel, QLD, Australia) at 150 V before transfer to a nitrocellulose membrane at 0.25 A for 45 min. After blocking for 30 min at room temperature Androgen decreases OPG protein in CaP cells K Vandyke et al with 5% skim milk powder diluted in PBS þ 0.1% Tween (SMP/PBST), membranes were incubated overnight at 41C with primary antibodies (rabbit anti-AR antibody N-20 used at 1/200 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, distributed by Applied Medical, Stafford, QLD, Australia; mouse anti-b-actin antibody AC-15 used at 1/10 000 dilution, Sigma-Aldrich) diluted in 5% SMP/PBST. Blots were washed three times with PBST for 5 min at room temperature followed by incubation for 1 h at room temperature with secondary antibody (goat anti-rabbit IgG-horseradish peroxidase (HRP), Santa Cruz and anti-mouse IgG-HRP, Santa Cruz, respectively) diluted to 1/10 000 with 5% SMP/PBST. Signal was detected using SuperSignal West Pico (Pierce) and exposure to Fuji Super RX medical X-Ray film (Fujifilm, Brookvale, NSW, Australia).
Statistical analysis
For analysis of dose-responses, effects of treatment were compared with control values by one-way analysis of variance followed by Dunnett's or Tukey's post-tests. As some values were below the detection limit of the ELISA used, the non-parametric Kruskal-Wallis followed by Dunn's post-test was used for comparison of basal OPG production between cell lines. In time course experiments, two-tailed t-tests were utilized to compare treatment groups with vehicle controls. Grubb's test was used to exclude outliers. A P-value of less than 0.05 was considered significant. Statistical tests were performed using GraphPad PRISM (GraphPad Software, San Diego, CA, USA).
Results
CaP cell lines produce OPG protein in vitro
The androgen-independent human CaP cell line PC-3 produced relatively high absolute levels of secreted OPG protein, whereas the androgen-responsive cell line LNCaP-FGC produced low levels of OPG protein ( Table 1 ). The immortalized normal prostatic epithelium-derived cell line PZ-HPV-7 produced intermediate levels of OPG protein. When corrected for total protein, PC-3 produced significantly more OPG protein than PZ-HPV-7 (Po0.05) and LNCaP-FGC (Po0.001). The androgen-responsive cell lines LAPC-4 and DuCaP produced undetectable levels of OPG protein over the 4-day period of culture and were excluded from further study.
Androgens decrease secreted OPG protein levels
Although after 3 days 5a-DHT had no detectable effect on LNCaP-FGC cells (P ¼ 0.3868), after 6 days, levels of secreted OPG protein were significantly decreased by almost 50% (Figure 1a ; P ¼ 0.0133). The overall response to 5a-DHT was biphasic, however, with maximal repression at 10
À10
-10
À9 M 5a-DHT (Po0.01 relative to vehicle control). At lower doses, levels of secreted OPG returned to those present in vehicle-treated cells.
Androgen treatment of PC-3 cells significantly decreased secreted OPG protein levels after 3 days at almost all doses tested, with a maximal repression of almost 50% at 10 À9 -10 À7 M 5a-DHT (Po0.01 relative to vehicle; Figure 1b) . After 6 days, although 10 À9 -10
À8 M 5a-DHT treatment decreased OPG protein levels to approximately 60% of vehicle-treated cells, this decrease was not statistically significant (P ¼ 0.2109).
5a-DHT does not affect OPG mRNA levels
Overall, when treated with 10 À9 M 5a-DHT for 6-72 h, there was no statistically significant change in OPG mRNA levels in LNCaP-FGC and PC-3 following treatment with 10 À9 M 5a-DHT. However, OPG mRNA levels were decreased by approximately 30% after 48 h in both cell lines compared with the vehicle control, although this did not reach statistical significance (Figure  2a and b) . To examine this further, we performed a doseresponse experiment at 48 h in both cell lines. Although OPG mRNA levels in LNCaP-FGC cells were decreased by approximately 50% with 10 À9 M 5a-DHT treatment for 48 h, 5a-DHT was not found to have a statistically significant effect on OPG mRNA expression levels vs vehicle control (P ¼ 0.1332; Figure 3a) . Although there was a trend towards a decrease in OPG mRNA levels with 5a-DHT treatment in PC-3 cells, again, this was not significant vs vehicle control (P ¼ 0.0986; Figure 3b ).
Flutamide antagonizes the effects of 5a-DHT on OPG protein levels in LNCaP-FGC cells
Consistent with previous reports, treatment with 10
À6 M flutamide or 5a-DHT alone elicited a significant increase in mitochondrial metabolic activity after 6 days of treatment (Po0.01 for both comparisons); whereas, cotreatment resulted in mitochondrial metabolic activity that was no different from the control wells (Figure 4a ).
Confirming our earlier findings (Figure 1a) , treatment with 5a-DHT alone decreased secreted OPG protein after 6 days in LNCaP-FGC cells (Po0.05; Figure 4b ). Although treatment with the AR-inhibitor flutamide reduced OPG protein levels to approximately 65% of vehicle-treated control, this decrease was not statistically significant. Pretreatment with flutamide 60 min before addition of 5a-DHT antagonized the inhibitory action of the 5a-DHT on protein production.
AR mRNA and protein expression in LNCaP-FGC and PC-3 cells
As OPG expression was altered by treatment with androgen in the PC-3 cell line, which is reported to be 
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AR-negative, we examined the AR status of the LNCaP-FGC and PC-3 cell lines used in these studies. Using RT-PCR, AR mRNA was detected in both cell lines and at similar levels, with complementary DNA (cDNA) detected at 27 cycles of amplification (Figure 5a ). Western blot analysis showed that, although AR protein was detected in LNCaP and LNCaP-FGC cells, it was not detected in PC-3 cells (Figure 5b ).
Discussion
As part of ongoing studies of factors important for the development of bone metastases during CaP progression, we have examined the effects of androgen on OPG levels in androgen-responsive LNCaP-FGC cells and androgen-independent PC-3 cells. The present study showed that androgen (5a-DHT) decreased OPG protein expression levels by approximately 50% in both LNCaP-FGC and PC-3 cells (Figure 1 ). In LNCaP-FGC cells, this effect was antagonized by the AR inhibitor, flutamide (Figure 4b ). Although treatment with 5a-DHT decreased OPG mRNA levels by 30-50%, these decreases were not found to be statistically significant (Figures 2 and 3) . Taken together, this suggests that, although the inhibitory effect of 5a-DHT on OPG protein expression levels may involve some modulation of mRNA expression levels, other mechanisms at the post-transcriptional level, including reduced protein synthesis, secretion or stability, or increased protein degradation, are likely to play a role in regulating the decreases in OPG protein expression levels by 5a-DHT. Similar effects by androgen on OPG protein expression levels have been reported in studies using primary human bone marrow stromal cells, the immortalized murine stromal cell line ST-2, and a human fetal osteoblast cell line transfected with AR. 20 The results showing altered OPG protein following 5a-DHT treatment in PC-3 cells were surprising, as PC-3 is considered to be androgen-independent. However, recent studies examining expression of AR mRNA and Androgen decreases OPG protein in CaP cells K Vandyke et al protein in PC-3 cells have produced conflicting results, 22, [24] [25] [26] although none of these investigations showed transcriptional activation of androgen-responsive genes by endogenous AR protein or any effect on proliferation of the PC-3 cells tested. 22, 27, 28 The PC-3 cells used in our study were found to express detectable levels of AR mRNA but did not produce detectable levels of AR protein as assessed by Western blot analysis ( Figure 5 ) and exhibited no growth response to androgens (data not shown), suggesting either that the effects of androgen in this cell line were mediated via AR-independent me- 
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K Vandyke et al chanisms or that levels of AR protein were too low to elicit activation of androgen-responsive genes. Alternatively, non-classical androgen signalling may be involved in decreasing OPG protein expression levels. There is growing evidence that steroid hormones can have rapid effects via pathways that cannot be explained by the classical route of action. Steroids can induce a response in cells lacking classical steroid receptors, such as mouse T lymphocytes and the murine macrophage/ monocyte cell lines RAW 264.7 and IC-21, through a mode of action that may involve binding at the plasma membrane. [29] [30] [31] [32] [33] [34] In both LNCaP-FGC and PC-3 ARÀ cell lines, testosterone has been shown to have actions at the plasma membrane that are independent of the intracellular AR. [33] [34] [35] [36] Furthermore, we analyzed 5 kb of the promoter sequence directly upstream of the OPG coding sequence using several transcription factor binding site software algorithms (MatchTM, P-Match, TFBIND and Alibaba 2.1), none of which revealed a putative AR binding site. Several potential AR binding sites were detected by MatInspector; however, given our findings in AR protein-negative PC-3 cells, it is unlikely that the AR is involved in mediating any inhibitory effects of androgen on OPG transcription in PC-3 cells.
Androgens regulate the expression of pro-and antiresorptive factors by bone cells in vitro. The expression of interleukin-6, tartrate-resistant acid phosphatase and cathepsin B, which increase bone resorption, is decreased by androgens, [37] [38] [39] whereas androgens increase the expression of factors, such as TGF-b 1 , that suppress bone resorption by inhibiting osteoclast activity and promoting osteoblast proliferation. [37] [38] [39] Androgen withdrawal therapy and decreased androgen levels related to the 'andropause' in men are associated with an increased risk of osteoporosis, decreased bone mineral density, and increased bone resorption, detected via the bone resorption markers serum osteocalcin and urinary hydroxyproline. 9 Treatment with testosterone at least partially prevents these effects and reduces the associated risk of fracture. 9, 10 There is some ambiguity as to whether these observed bone mineral density effects are directly owing to androgens or are a result of aromatization of androgens: the activity of aromatases, which convert androgens to estrogen, may partly account for the bone preservation in men with normal levels of androgen that is lost with androgen withdrawal. 40 The net bone-protective effects of androgens in vivo may appear inconsistent with our finding that androgen decreases OPG production by CaP cells in vitro. The competing effects of androgens on CaP and bone cells within the bone could result in a local bone microenvironment that favors either bone resorption or protection of the bone. The absolute levels of OPG and RANKL expression are altered in many cancers, including CaP, that have a tendency to metastasize to the bone. 41, 42 At the mRNA level, increasing RANKL/OPG ratio is associated with increased bone resorption in osteolytic malignancies, including bone metastases from kidney, lung and breast cancers, 43 suggesting that it is the relative quantity of OPG and RANKL in the bone microenvironment that determines whether osteoclastogenesis and osteolytic activity occur. Further studies to determine the effects of androgens on CaP RANKL expression should indicate whether the inhibitory effects on OPG production would result in a net change in the OPG/RANKL axis or if they are counteracted by a corresponding decrease in RANKL production.
